Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NICE technology appraisal guidance 473
National Institute for Health and Care Excellence (NICE)
Record ID 32018011557
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta473
Year Published:
2017
URL for published report:
https://www.nice.org.uk/guidance/ta473
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Cetuximab
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.